Abstract:Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly 25% of the population and is the leading cause for liver-related mortality. Bariatric surgery is a well-known treatment for MASLD and obesity. Understanding the fundamental mechanisms by which bariatric surgery can alter MASLD can lead to new avenues of therapy and research. Previous studies have identified the microbiome's role in bariatric surgery and in inflammatory immune cell populations. The host innate immune system modulates hepatic inflammation and fibrosis, and thus the progression of MASLD. The precise role of immune cell types in the pathogenesis of MASLD remains an active area of investigation. The aim of this study was to understand the interplay between microbiota composition post-bariatric surgery and the immune system in MASLD. Methods: Eighteen morbidly obese females undergoing sleeve gastrectomy were followed pre-and post-surgery. Stool from four patients, showing resolved MASLD post-surgery with sustained weight loss, was transplanted into antibiotic treated mice. Mice received pre-or post-surgery stool and were fed a standard or high-fat diet. Bodyweight, food intake, and physiological parameters were tracked weekly. Metabolic parameters were measured post-study termination. Results: The human study revealed that bariatric surgery led to significant weight loss (p > 0.05), decreased inflammatory markers, and improved glucose levels six months post-surgery. Patients with weight loss of 20% or more showed distinct changes in blood metabolites and gut microbiome composition, notably an increase in Bacteroides. The mouse model confirmed surgery-induced microbiome changes to be a major factor in the reduction of markers and attenuation of MASLD progression. Mice receiving post-surgery fecal transplants had significantly less weight gain and liver steatosis compared to pre-surgery recipients. There was also a significant decrease in inflammatory cytokines interferon gamma, interleukin 2, interleukin 15, and mig. This was accompanied by alterations in liver immunophenotype, including an increase in natural killer T cells and reduction of Kupfer cells in the post-surgery transplant group. Discussion: Our findings suggest surgery induced microbial changes significantly reduce inflammatory markers and fatty liver progression. The results indicate a potential causal link between the microbiome and the host immune system, possibly mediated through modulation of liver NKT and Kupffer cells.

Lipid metabolic reprogramming mediated by circulating Nrg4 alleviates metabolic dysfunction-associated steatotic liver disease during the early recovery phase after sleeve gastrectomy

Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality

Endoplasmic Reticulum Stress Inhibitor May Substitute for Sleeve Gastrectomy to Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease.

Multiomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomy

Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: A prospective cohort study

Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery

Therapeutic Effects of Metabolic Bariatric Surgery on Non-Alcoholic Fatty Liver Disease Are Influenced by Low Density Lipoprotein

Increased plasma genistein after bariatric surgery could promote remission of NAFLD in patients with obesity

Amelioration of NAFLD by sleeve gastrectomy-triggered hepatocyte regeneration in mice - experimental research

Longitudinal changes of serum metabolomic profile after laparoscopic sleeve gastrectomy in obesity

Key genes involved in nonalcoholic steatohepatitis improvement after bariatric surgery

Downregulation of Setdb2 Promotes Alternative Activation of Macrophages Via the PI3K/Akt Pathway to Attenuate NAFLD after Sleeve Gastrectomy

Effect of metabolic surgery in treatment of severe obesity with nonalcoholic fatty liver disease

Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease

Characterization of the plasma metabolome and lipidome in response to sleeve gastrectomy and gastric bypass surgeries reveals molecular patterns of surgical weight loss

Sleeve Gastrectomy Ameliorated High-Fat Diet (Hfd)-Induced Non-Alcoholic Fatty Liver Disease and Upregulated the Nicotinamide Adenine Dinucleotide +/ Sirtuin-1 Pathway in Mice.

Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system

Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery

Targeting Bile Acid-Activated Receptors in Bariatric Surgery.

Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study

Effects of Sleeve Gastrectomy on Lipid and Energy Metabolism in ZDF Rats Via PI3K/AKT Pathway.